Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Tuesday, January 9th.
Other equities research analysts have also recently issued reports about the company. Needham & Company LLC upped their price target on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Friday, December 1st. Piper Jaffray Companies reissued a “buy” rating and issued a $19.00 target price on shares of Amphastar Pharmaceuticals in a report on Sunday, September 17th. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Thursday, October 19th. Jefferies Group set a $19.00 target price on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, BMO Capital Markets upped their price target on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a report on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $20.83.
Shares of Amphastar Pharmaceuticals (NASDAQ AMPH) traded down $0.28 during trading on Tuesday, reaching $18.64. The company’s stock had a trading volume of 182,918 shares, compared to its average volume of 168,282. The company has a quick ratio of 1.86, a current ratio of 3.08 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a 1-year low of $12.05 and a 1-year high of $19.95. The stock has a market cap of $900.66, a PE ratio of 130.60, a P/E/G ratio of 1.37 and a beta of 1.69.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The firm had revenue of $57.90 million for the quarter, compared to analysts’ expectations of $57.23 million. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The business’s revenue was down 9.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 earnings per share. sell-side analysts forecast that Amphastar Pharmaceuticals will post -0.04 earnings per share for the current year.
In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 6,226 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $19.67, for a total value of $122,465.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jason B. Shandell sold 18,627 shares of the company’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $19.42, for a total value of $361,736.34. The disclosure for this sale can be found here. In the last quarter, insiders have sold 91,690 shares of company stock valued at $1,734,084. 11.10% of the stock is owned by company insiders.
Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Amphastar Pharmaceuticals by 10.8% during the second quarter. Vanguard Group Inc. now owns 2,414,797 shares of the company’s stock worth $43,128,000 after purchasing an additional 235,033 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Amphastar Pharmaceuticals by 17.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,558,113 shares of the company’s stock worth $27,844,000 after purchasing an additional 226,271 shares in the last quarter. Teachers Advisors LLC grew its position in shares of Amphastar Pharmaceuticals by 1.1% during the second quarter. Teachers Advisors LLC now owns 549,149 shares of the company’s stock worth $9,808,000 after purchasing an additional 6,196 shares in the last quarter. Northern Trust Corp grew its position in shares of Amphastar Pharmaceuticals by 2.0% during the second quarter. Northern Trust Corp now owns 485,706 shares of the company’s stock worth $8,675,000 after purchasing an additional 9,672 shares in the last quarter. Finally, UBS Asset Management Americas Inc. grew its position in shares of Amphastar Pharmaceuticals by 143.0% during the second quarter. UBS Asset Management Americas Inc. now owns 362,947 shares of the company’s stock worth $6,482,000 after purchasing an additional 213,572 shares in the last quarter. Hedge funds and other institutional investors own 43.94% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “BidaskClub Downgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to Strong Sell” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/31/bidaskclub-lowers-amphastar-pharmaceuticals-amph-to-strong-sell.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.